About Us
OUR MISSION IS TO LEAD AN EVOLUTION IN TRANSLATIONAL ONCOLOGY VIA NOVEL INSIGHTS INTO HUMAN TUMOR BIOLOGY GENERATED BY THE CIVO PLATFORM
About Presage
Presage’s patented CIVO® (Comparative In Vivo Oncology) technology delivers microdoses of multiple drugs to different regions of a tumor, while the tumor is still in the patient. Observing molecular and cellular responses to drugs and combinations in a naturally occurring tumor has the potential to provide a more detailed understanding of tumor biology. This method directly captures a patients own immune system, tumor microenvironment, and genetic background. It is Presage’s mission to improve the way that new drugs are developed and targeted, with the goal of ultimately providing more effective treatments to patients with cancer.
Presage collaborates with other innovators who want to be at the forefront of oncology drug development. We work together to understand the myriad complexities of the tumor microenvironment and with our CIVO platform, explore the most important model of cancer – the human patient.
Preclinical CIVO Offerings Available
CIVO highlights immune effects in syngeneic models
Preclinical CIVO Offerings Available
CIVO highlights immune effects in syngeneic models
- Experienced preclinical team
- In-house vivarium & IACUC
- Full tumor model, histology and image analysis support
- Excellent for pilot studies prior to Clinical CIVO
- Amenable to ALL drug modalities
- Small molecule
- I-O biologics
- Complex biologics (antibody-drug conjugates
- Novel delivery nanoparticles (exp. Exosomes)
- Live cell therapies (exp. CAR-T)
- Any combination of the above without drug reformulation!
Cancer Drug Development Needs More Predictive Platforms For Testing Candidate Agents
One important bottleneck in oncology drug development is the inability of preclinical models to accurately model the tumor microenvironment in human patients.
CIVO IS A PIONEERING SOLUTION TO A HOST OF FUNDAMENTAL PROBLEMS INHERENT IN ONCOLOGY DRUG DISCOVERY
Nine US Patents Issued
Presage's Partners
A pioneering solution, turnkey operation, revenue-generating partnerships2016 - 2021
CIVO IS A PIONEERING SOLUTION TO A HOST OF FUNDAMENTAL PROBLEMS INHERENT IN ONCOLOGY DRUG DISCOVERY
Nine Patents Issued
in the United States
Nine issued US patents
“A method of evaluating one or more candidate agents, wherein at least one of the one or more candidate agents is a drug, comprising: introducing the one or more candidate agents to one or more positions in a solid tissue, and; evaluating effectiveness of the candidate agents on the solid tissue, wherein the introducing step is in vivo, and wherein the solid tissue is a tumor.”
